- Home
- VRCA vs BOLD Comparison
VRCA vs BOLD Comparison
Compare VRCA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRCA | BOLD |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 26.9M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | VRCA | BOLD |
|---|---|---|
| Price | $8.30 | $1.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $17.00 | $4.00 |
| AVG Volume (30 Days) | ★ 211.3K | 133.7K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,829,000.00 | N/A |
| Revenue This Year | $373.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $1.00 |
| 52 Week High | $9.82 | $3.12 |
Technical Indicators
Market Signals| Indicator | VRCA | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 61.19 | 52.99 |
| Support Level | $7.60 | $1.15 |
| Resistance Level | $9.02 | $1.24 |
| Average True Range (ATR) | 0.87 | 0.08 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 65.99 | 36.00 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.